198 results on '"Crossman, David K."'
Search Results
2. L-2-hydroxyglutarate remodeling of the epigenome and epitranscriptome creates a metabolic vulnerability in kidney cancer models
3. Late-Stage Skeletal Muscle Transcriptome in Duchenne muscular dystrophy shows a BMP4-Induced Molecular Signature
4. Carmofur prevents cell cycle progression by reducing E2F8 transcription in temozolomide-resistant glioblastoma cells
5. Endothelial samplingin situenables genetic characterization of vein of Galen Malformation
6. Gene-Level Analysis of Anthracycline-Induced Cardiomyopathy in Cancer Survivors
7. Epigenetic switch reshapes epithelial progenitor cell signatures and drives inflammatory pathogenesis in hidradenitis suppurativa
8. Oxalate disrupts monocyte and macrophage cellular function via Interleukin-10 and mitochondrial reactive oxygen species (ROS) signaling
9. HSP90, a common therapeutic target for suppressing skin injury caused by exposure to chemically diverse classes of blistering agents
10. Altered Peripheral Blood Gene Expression in Childhood Cancer Survivors With Anthracycline‐Induced Cardiomyopathy – A COG‐ALTE03N1 Report
11. ST6GAL1 sialyltransferase promotes acinar to ductal metaplasia and pancreatic cancer progression
12. Novel Biomarkers and Distinct Transcriptomic Profile of Barrett's Esophagus Epithelial Stem Cells
13. Identification of novel hypermethylated or hypomethylated CpG sites and genes associated with anthracycline-induced cardiomyopathy
14. Accelerated cystogenesis by dietary protein load is dependent on, but not initiated by kidney macrophages
15. Haptoglobin Gene Expression and Anthracycline-Related Cardiomyopathy in Childhood Cancer Survivors
16. Cytokine storm–based mechanisms for extrapulmonary manifestations of SARS-CoV-2 infection
17. Metabolic Adaptation to Tyrosine Kinase Inhibition in Leukemia Stem Cells
18. Cx3cr1 controls kidney resident macrophage heterogeneity
19. Data from Suppression of SIN3A by miR-183 Promotes Breast Cancer Metastasis
20. Supplementary Figure from Suppression of SIN3A by miR-183 Promotes Breast Cancer Metastasis
21. Supplementary Figure 5 from Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma
22. Supplementary Tables 1 - 7 from Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma
23. Data from Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma
24. Data from Suppression of SIN3A by miR-183 Promotes Breast Cancer Metastasis
25. Supplementary Tables 1 - 7 from Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma
26. Supplementary Figure 2 from Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma
27. Data from Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma
28. Supplementary Figure 1 from Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma
29. Supplementary Table, Figure Legends from Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma
30. Supplementary Figure 3 from Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma
31. Supplementary Figure 2 from Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma
32. Supplementary Figure 5 from Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma
33. Supplementary Figure 3 from Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma
34. Supplementary Figure 4 from Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma
35. Supplementary Figure from Suppression of SIN3A by miR-183 Promotes Breast Cancer Metastasis
36. Supplementary Figure 4 from Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma
37. Supplementary Table, Figure Legends from Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma
38. Supplementary Data File S7 from Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors
39. Supplementary Data File S4 from Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors
40. Supplementary Data File S5 from Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors
41. Supplementary Data File S6 from Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors
42. Supplementary Data File S6 from Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors
43. Supplemental figures from Biochemical and Epigenetic Insights into L-2-Hydroxyglutarate, a Potential Therapeutic Target in Renal Cancer
44. Supplemental Table S1 from Biochemical and Epigenetic Insights into L-2-Hydroxyglutarate, a Potential Therapeutic Target in Renal Cancer
45. Supplementary Data File S3 from Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors
46. Supplementary Data File S1 from Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors
47. Supplementary Data File S2 from Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors
48. Data from Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors
49. Supplementary Data File S5 from Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors
50. Supplementary Data File S1 from Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.